Exploring the role of MIA-602 in overcoming doxorubicin-resistance in acute myeloid leukemia

A brand new analysis paper titled “Exploring the function of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia” has been published in Oncotarget.

Acute myeloid leukemia (AML) is characterised by the speedy proliferation of mutagenic hematopoietic progenitors within the bone marrow. Standard therapies embrace chemotherapy and bone marrow stem cell transplantation; nonetheless, they’re usually related to poor prognosis. Notably, development hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been proven to impede the expansion of assorted human most cancers cell strains, together with AML.

On this new research, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally, and Joaquin J. Jimenez from the College of Miami, Florida Atlantic College and Veterans Affairs Medical Middle, Miami examined the impression of MIA-602 as monotherapy and together with doxorubicin on three doxorubicin-resistant AML cell strains, KG-1A, U-937, and Ok-562.

The researchers observe, “Given the function of GHRH in a number of most cancers sorts, it’s potential that GHRH antagonists might supply an alternate therapy method for AML in addition to drug-resistant AML, which can circumvent the negative effects related to normal chemotherapy.”

The in vitro outcomes revealed a major discount in cell viability for all handled wild-type cells. Doxorubicin-resistant clones have been equally prone to MIA-602 because the wild-type counterpart. Their in vivo experiment of xenografted nude mice with doxorubicin-resistant Ok-562 revealed a discount in tumor quantity with MIA-602 therapy in comparison with management.

“Our research demonstrates that these three AML cell strains, and their Doxorubicin-resistant clones, are prone to GHRH antagonist MIA-602,” the group concludes.

Supplied by
Affect Journals LLC